Voyager and Novartis reach over $1.7 billion partnership to develop next-generation AAV gene therapy

On March 9, Voyager Therapeutics announced that it has entered into a licensing and research and development agreement with Novartis, which gives Novartis the right to obtain development rights to the innovative AAV capsids developed by Voyager's AAV capsid discovery platform, targeting three unpublished AAV capsids.

AAV vector is one of the important vectors for delivering a variety of gene medicine products such as gene therapy

According to the cooperation agreement, Novartis has the right to evaluate the innovative capsids discovered on the Voyager technology platform, and has full access to the development rights of specific capsids for the development of AAV gene therapy targeting CNS targets

References:

[1] Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs.

(Original abridged)